Pasireotide for the treatment of acromegaly

References

• Taboada GF, van Haute FR, Correa LL, et al. Etiologic aspects and management of acromegaly. Arq Bras Endocrinol Metabol. 2005 Oct;49(5):626–640.
   PubMedGoogle Scholar
• Mestron A, Webb SM, Astorga R, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish acromegaly registry (Registro Espanol de Acromegalia, REA). Eur J Endocrinol. 2004 Oct;151(4):439–446.
   PubMed Web of Science ®Google Scholar
• Tjornstrand A, Gunnarsson K, Evert M, et al. The incidence rate of pituitary adenomas in western Sweden for the period 2001-2011. Eur J Endocrinol. 2014 Oct;171(4):519–526.
   PubMed Web of Science ®Google Scholar
• Hoskuldsdottir GT, Fjalldal SB, Sigurjonsdottir HA. The incidence and prevalence of acromegaly, a nationwide study from 1955 through 2013. Pituitary. 2015 Dec;18(6):803–807.
   PubMed Web of Science ®Google Scholar
• Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010 Mar;72(3):377–382.
   PubMed Web of Science ®Google Scholar
• Reid TJ, Post KD, Bruce JN, et al. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf). 2010 Feb;72(2):203–208.
   PubMed Web of Science ®Google Scholar
• Colao A, Ferone D, Marzullo P, et al. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev. 2004 Feb;25(1):102–152.
   PubMed Web of Science ®Google Scholar
• Casini AF, Neto LV, Fontes R, et al. Aortic root ectasia in patients with acromegaly: experience at a single center. Clin Endocrinol (Oxf). 2011 Oct;75(4):495–500.
   PubMed Web of Science ®Google Scholar
• Santos Silva CM, Gottlieb I, Volschan I, et al. Low frequency of cardiomyopathy using cardiac magnetic resonance imaging in an acromegaly contemporary cohort. J Clin Endocrinol Metab. 2015 Dec; 100(12):4447–4455.
   PubMed Web of Science ®Google Scholar
• Colao A, Pivonello R, Grasso LF, et al. Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. Eur J Endocrinol. 2011 Nov;165(5):713–721.
   PubMed Web of Science ®Google Scholar
• Prencipe N, Floriani I, Guaraldi F, et al. ACROSCORE: a new and simple tool for the diagnosis of acromegaly, a rare and underdiagnosed disease. Clin Endocrinol (Oxf). 2015 Oct 3. doi:10.1111/cen.12959. [Epub ahead of print].
   PubMedGoogle Scholar
• Correa LL, Taboada GF, Van Haute FR, et al. Evaluation of glucose metabolism in acromegalic patients before and after treatment with octreotide LAR. Arq Bras Endocrinol Metabol. 2008 Feb;52(1):55–64.
   PubMed Web of Science ®Google Scholar
• Alexopoulou O, Bex M, Kamenicky P, et al. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary. 2014 Feb;17(1):81–89.
   PubMed Web of Science ®Google Scholar
• Van Haute FR, Taboada GF, Correa LL, et al. Prevalence of sleep apnea and metabolic abnormalities in patients with acromegaly and analysis of cephalometric parameters by magnetic resonance imaging. Eur J Endocrinol. 2008 Apr;158(4):459–465.
   PubMed Web of Science ®Google Scholar
• Roemmler J, Gutt B, Fischer R, et al. Elevated incidence of sleep apnoea in acromegaly-correlation to disease activity. Sleep Breath. 2012 Dec;16(4):1247–1253.
   PubMed Web of Science ®Google Scholar
• Oktayoglu P, Nas K, Kilinc F, et al. Assessment of the presence of carpal tunnel syndrome in patients with diabetes mellitus, hypothyroidism and acromegaly. J Clin Diagn Res. 2015 Jun;9(6):OC14OC18.
   Google Scholar
• Wassenaar MJ, Biermasz NR, Van Duinen N, et al. High prevalence of arthropathy, according to the definitions of radiological and clinical osteoarthritis, in patients with long-term cure of acromegaly: a case-control study. Eur J Endocrinol. 2009 Mar;160(3):357–365.
   PubMed Web of Science ®Google Scholar
• Kropf LL, Madeira M, Vieira Neto L, et al. Functional evaluation of the joints in acromegalic patients and associated factors. Clin Rheumatol. 2013 Jul;32(7):991–998.
   PubMed Web of Science ®Google Scholar
• Anthony JR, Ioachimescu AG. Acromegaly and bone disease. Curr Opin Endocrinol Diabetes Obes. 2014 Dec;21(6):476–482.
   PubMed Web of Science ®Google Scholar
• Madeira M, Neto LV, Torres CH, et al. Vertebral fracture assessment in acromegaly. J Clin Densitom. 2013 Apr-Jun;16(2):238–243.
   PubMed Web of Science ®Google Scholar
• Benfante A, Ciresi A, Bellia M, et al. Early lung function abnormalities in acromegaly. Lung. 2015 Jun;193(3):393–399.
   PubMed Web of Science ®Google Scholar
• Camilo GB, Carvalho AR, Machado DC, et al. Correlations between forced oscillation technique parameters and pulmonary densitovolumetry values in patients with acromegaly. Braz J Med Biol Res. 2015 Oct;48(10):877–885.
   PubMed Web of Science ®Google Scholar
• Sala E, Ferrante E, Locatelli M, et al. Diagnostic features and outcome of surgical therapy of acromegalic patients: experience of the last three decades. Hormones (Athens). 2014 JanMar;13(1):95–103.
   PubMedGoogle Scholar
• Reverter JL, Fajardo C, Resmini E, et al. Benign and malignant nodular thyroid disease in acromegaly. Is a routine thyroid ultrasound evaluation advisable? PLoS One. 2014;9(8):e104174.
   Google Scholar
• Uchoa HB, Lima GA, Correa LL, et al. Prevalence of thyroid diseases in patients with acromegaly: experience of a Brazilian center. Arq Bras Endocrinol Metabol. 2013 Dec;57(9):685–690.
   PubMed Web of Science ®Google Scholar
• Yamamoto M, Fukuoka H, Iguchi G, et al. The prevalence and associated factors of colorectal neoplasms in acromegaly: a single center based study. Pituitary. 2015 Jun;18(3):343–351.
   PubMed Web of Science ®Google Scholar
• Dekkers OM, Biermasz NR, Pereira AM, et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab. 2008 Jan;93(1):61–67.
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol. 2008 Aug;159(2):89–95.
   PubMed Web of Science ®Google Scholar
• Biermasz NR, Dekker FW, Pereira AM, et al. Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. J Clin Endocrinol Metab. 2004 Jun;89(6):2789–2796.
   PubMed Web of Science ®Google Scholar
• Holdaway IM, Rajasoorya RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab. 2004 Feb;89(2):667–674.
   PubMed Web of Science ®Google Scholar
• Katznelson L, Laws ER Jr., Melmed S, et al. Acromegaly: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014 Nov;99(11):3933–3951.
   PubMed Web of Science ®Google Scholar
• Vieira Neto L, Abucham J, Araujo LA, et al. [Recommendations of neuroendocrinology department from Brazilian society of endocrinology and metabolism for diagnosis and treatment of acromegaly in Brazil]. Arq Bras Endocrinol Metabol. 2011 Mar;55(2):91–105.
   PubMed Web of Science ®Google Scholar
• Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol. 2013 Aug;34(3):228–252.
   PubMed Web of Science ®Google Scholar
• Murray RD, Kim K, Ren SG, et al. The novel somatostatin ligand (SOM230) regulates human and rat anterior pituitary hormone secretion. J Clin Endocrinol Metab. 2004 Jun;89(6):3027–3032.
   PubMed Web of Science ®Google Scholar
• Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol. 1999 Jul;20(3):157–198.
   PubMed Web of Science ®Google Scholar
• Schmid HA. Pasireotide (SOM230): development, mechanism of action and potential applications. Mol Cell Endocrinol. 2008 May 14;286(12):69–74.
   PubMed Web of Science ®Google Scholar
• Neto LV, Machado Ede O, Luque RM, et al. Expression analysis of dopamine receptor subtypes in normal human pituitaries, nonfunctioning pituitary adenomas and somatotropinomas, and the association between dopamine and somatostatin receptors with clinical response to octreotide-LAR in acromegaly. J Clin Endocrinol Metab. 2009 Jun;94(6):1931–1937.
   PubMed Web of Science ®Google Scholar
• Taboada GF, Luque RM, Bastos W, et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol. 2007 Jan;156(1):65–74.
   PubMed Web of Science ®Google Scholar
• Taboada GF, Luque RM, Neto LV, et al. Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR. Eur J Endocrinol. 2008 Mar;158(3):295–303.
   PubMed Web of Science ®Google Scholar
• Freda PU, Katznelson L, van der Lely AJ, et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab. 2005 Aug;90(8):4465–4473.
   PubMed Web of Science ®Google Scholar
• Wildemberg LE, Neto LV, Costa DF, et al. Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs. J Endocrinol Invest. 2013 Jan;36(1):38–43.
   PubMed Web of Science ®Google Scholar
• Colao A, Bronstein MD, Freda P, et al. Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. 2014 Mar;99(3):791–799.
   PubMed Web of Science ®Google Scholar
• Gadelha MR, Bronstein MD, Brue T, et al. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2014 Nov;2(11):875–884.
   PubMed Web of Science ®Google Scholar
• Mercado M, Borges F, Bouterfa H, et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol (Oxf). 2007 Jun;66(6):859–868.
   PubMed Web of Science ®Google Scholar
• Colao A, Cappabianca P, Caron P, et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol (Oxf). 2009 May;70(5):757–768.
   PubMed Web of Science ®Google Scholar
• Gatto F, Feelders RA, van der Pas R, et al. Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2012 Jan;98(1):E66E71.
   Google Scholar
• Gadelha MR, Kasuki L, Korbonits M. Novel pathway for somatostatin analogs in patients with acromegaly. Trends Endocrinol Metab. 2013 May;24(5):238–246.
   PubMed Web of Science ®Google Scholar
• Kasuki L, Vieira Neto L, Wildemberg LE, et al. AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression. Endocr Relat Cancer. 2012 Jun;19(3):L25L29.
   Google Scholar
• Kasuki L, Wildemberg LE, Neto LV, et al. Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern. Eur J Endocrinol. 2013 Aug;169(2):217–223.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, Muhammad A, Van Der Lelij AJ. Pegvisomant treatment in acromegaly. Neuroendocrinology. 2015 Mar 19. [Epub ahead of print].
   Google Scholar
• Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000 Apr 20;342(16):1171–1177.
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Biller BM, Brue T, et al. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab. 2012 May;97(5):1589–1597.
   PubMed Web of Science ®Google Scholar
• Kasuki L, Vieira Neto L, Gadelha MR. Cabergoline treatment in acromegaly: cons. Endocrine. 2014 Jun;46(2):220–225.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, van Aken MO, Janssen JA, et al. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab. 2007 Dec;92(12):4598–4601.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, Franck SE, de Rooij FW, et al. Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2014 Oct;99(10):3644–3652.
   PubMed Web of Science ®Google Scholar
• van der Lely AJ, Bernabeu I, Cap J, et al. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol. 2011 Mar;164(3):325–333.
   PubMed Web of Science ®Google Scholar
• Feenstra J, de Herder WW, Ten Have SM, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet. 2005 May 713;365(9471):1644–1646.
   PubMed Web of Science ®Google Scholar
• Neggers SJ, De Herder WW, Janssen JA, et al. Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol. 2009 Apr;160(4):529–533.
   PubMed Web of Science ®Google Scholar
• Trainer PJ, Ezzat S, D’Souza GA, et al. A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol (Oxf). 2009 Oct;71(4):549–557.
   PubMed Web of Science ®Google Scholar
• Schofl C, Grussendorf M, Honegger J, et al. Failure to achieve disease control in acromegaly: cause analysis by a registry-based survey. Eur J Endocrinol. 2015 Apr;172(4):351–356.
   PubMed Web of Science ®Google Scholar
• Bex M, Abs R, T’Sjoen G, et al. AcroBel–the Belgian registry on acromegaly: a survey of the ‘real-life’ outcome in 418 acromegalic subjects. Eur J Endocrinol. 2007 Oct;157(4):399–409.
   PubMed Web of Science ®Google Scholar
• Giustina A, Mazziotti G, Maffezzoni F, et al. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors. Expert Opin Investig Drugs. 2014 Dec;23(12):1619–1635.
   PubMed Web of Science ®Google Scholar
• Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002 May;146(5):707–716.
   PubMed Web of Science ®Google Scholar
• Golor G, Hu K, Ruffin M, et al. A first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteers. Drug Des Devel Ther. 2012;6:71–79.
   PubMed Web of Science ®Google Scholar
• Chen X, Shen G, Jiang J, et al. Pharmacokinetics and safety of subcutaneous pasireotide and intramuscular pasireotide long-acting release in Chinese male healthy volunteers: a phase I, single-center, open-label, randomized study. Clin Ther. 2014 Aug 1;36(8):1196–1210.
   PubMed Web of Science ®Google Scholar
• Petersenn S, Bollerslev J, Arafat AM, et al. Pharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: a randomized, multicenter, open-label, phase I study. J Clin Pharmacol. 2014 Nov;54(11):1308–1317.
   PubMed Web of Science ®Google Scholar
• Lin TH, Hu K, Flarakos J, et al. Assessment of the absorption, metabolism and excretion of [(1)(4)C]pasireotide in healthy volunteers using accelerator mass spectrometry. Cancer Chemother Pharmacol. 2013 Jul;72(1):181–188.
   PubMed Web of Science ®Google Scholar
• Horsmans Y, Hu K, Ruffin M, et al. Effect of hepatic impairment on the pharmacokinetics of pasireotide (SOM230): results from a multicenter phase I study. J Clin Pharmacol. 2012 Apr;52(4):552–558.
   PubMed Web of Science ®Google Scholar
• Weckbecker G, Briner U, Lewis I, et al. SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology. 2002 Oct;143(10):4123–4130.
   PubMed Web of Science ®Google Scholar
• Hofland LJ, Van Der Hoek J, van Koetsveld PM, et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. J Clin Endocrinol Metab. 2004 Apr;89(4):1577–1585.
   PubMed Web of Science ®Google Scholar
• van der Hoek J, de Herder WW, Feelders RA, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab. 2004 Feb;89(2):638–645.
   PubMed Web of Science ®Google Scholar
• Petersenn S, Schopohl J, Barkan A, et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. J Clin Endocrinol Metab. 2010 Jun;95(6):2781–2789.
   PubMed Web of Science ®Google Scholar
• Sheppard M, Bronstein MD, Freda P, et al. Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study. Pituitary. 2015 Jun;18(3):385–394.
   PubMed Web of Science ®Google Scholar
• Freda P, Fleseriu M, Van der Lely AJ, et al. Switching patients with acromegaly from octreotide LAR to pasireotide LAR improves biochemical control: crossover extension to a randomized, double-blind, multicenter, phase III study. Poster presentation. Endocr Rev. 2013;33(3 Suppl):SUN 741.
   Google Scholar
• Breitschaft A, Hu K, Darstein C, et al. Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: a single-center, phase i, randomized, four-way crossover study. J Clin Pharmacol. 2014 Jan;54(1):75–86.
   PubMed Web of Science ®Google Scholar
• Gadelha M, Brue T, Fleseriu M, et al. Proactive monitoring and early intervention in the management of pasireotide-induced hyperglycemia: lessons from the phase III, 24-week PAOLA study. Poster presentation. Endoc Rev. 2015;36(2 Suppl):LBT 079.
   Google Scholar
• Breitschaft A, Hu K, Hermosillo Resendiz K, et al. Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study. Diabetes Res Clin Pract. 2014 Mar;103(3):458–465.
   PubMed Web of Science ®Google Scholar
• Henry RR, Ciaraldi TP, Armstrong D, et al. Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteers. J Clin Endocrinol Metab. 2013 Aug;98(8):3446–3453.
   PubMed Web of Science ®Google Scholar
• Colao A, Gu F, Gadelha M, et al. Metformin-based oral antidiabetic therapy is effective at controlling hyperglycemia associated with pasireotide in patients with acromegaly. Poster presentation. Endocr Rev. 2015;36(2 Suppl):PP09-2.
   Google Scholar
• Colao A, De Block C, Gaztambide MS, et al. Managing hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendations. Pituitary. 2013 Apr;17(2):180–186.
   Web of Science ®Google Scholar
• Reznik Y, Bertherat J, Borson-Chazot F, et al. Management of hyperglycaemia in Cushing’s disease: experts’ proposals on the use of pasireotide. Diabetes Metab. 2012 Feb;39(1):34–41.
   PubMed Web of Science ®Google Scholar
• Gadelha MR. A paradigm shift in the medical treatment of acromegaly: from a ‘trial and error’ to a personalized therapeutic decision-making process. Clin Endocrinol (Oxf). 2015 Jul;83(1):1–2.
   PubMed Web of Science ®Google Scholar